7-methyl indole analogs and dosage forms containing the same

A composition comprising:

• a pharmaceutically acceptable carrier;
• and
• 0.01 mg to 1,000 mg of at least one compound selected from compounds of Formula I:
• wherein
• X and Y are each independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, and optionally substituted C2-C8 alkenyl, or Y is taken together with X and the nitrogen atom therebetween to form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9;
• W1 is selected from NR9, O, Se, Se(O), SeO2, S, S(O), and SO2;
• W2 is selected from —CD2-, —CHD-, —(CD2)2-, —CH2— and —(CH2)2—;
• Z4 is CR4;
• Z5 is selected from N and CR5;
• Z6 is selected from N and CR6;
• Z7 is CR7;
• R2, R3, R3′, and R6 are each independently selected from hydrogen, deuterium, —N(R9) 2, —SR9, halo, optionally substituted C1-C8 alkyl, —C1-C8 alkoxy, and optionally substituted C2-C8 alkenyl, or Y is absent and R3 taken together with carbon to which it is attached and the nitrogen atom to which X is attached form a 3- to 7-membered heterocyclic ring optionally including 1 to 2 additional ring heteromoieties selected from O, S, S(O), SO2, and NR9;
• R4 is selected from hydroxyl, C1-C8 alkoxy, —OC(O)R8, —OC(O)OR8, —OP(O)O2 (R9)2, and —OSO2R8;
• R5 is selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, halo, hydroxyl, —N(R9)2, —SR9, —C1-C8 alkoxy, —OC(O)R8, —OC(O)OR8, —OP(O)O2 (R9)2, and —OSO2R8;
• R7 is C1-C8 alkyl;
• R8 is selected from optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted aryl;
• R9 is independently selected from hydrogen, deuterium, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted aryl;
• and
• salts, solvates, hydrates, and prodrugs thereof.